Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15317638 | 0.86 | HDAC6 (0.63) | ALDH1A1SMN1; SMN2MAPK1EPHX2HDAC6 | |
| SCHEMBL12993901 | 0.85 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2TSHRCYP3A4LMNA | |
| SCHEMBL8372164 | 0.85 | MEN1 (0.61) | ALDH1A1SMN1; SMN2NPSR1TSHRCYP3A4 | |
| SCHEMBL25735895 | 0.85 | HDAC6 (0.66) | ALDH1A1SMN1; SMN2MAPK1EPHX2HDAC6 | |
| SCHEMBL13745563 | 0.83 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2NPSR1TSHRCYP3A4 | |
| SCHEMBL13745754 | 0.83 | ALDH1A1 (0.62) | ALDH1A1EPHX2 | |
| SCHEMBL13746186 | 0.83 | NPSR1 (0.72) | ALDH1A1NPSR1EPHX2TSHRTDP1 | |
| SCHEMBL15317639 | 0.82 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2MAPK1EPHX2LMNA | |
| SCHEMBL26154399 | 0.82 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2MAPK1EPHX2HDAC6 | |
| SCHEMBL13746194 | 0.81 | POLB (0.62) | ALDH1A1NPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377945-B2 | Small molecule inhibitors of spleen tyrosine kinase (SYK) | RIGEL PHARMACEUTICALS INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20100316649-A1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | MIDCAP FINANCIAL TRUST | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100316649-A1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | SYK, BTK, LCK | ALDH1A1 4307/4885SMN1; SMN2 2568/4885MAPK1 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.